CRSP:NSD-CRISPR Therapeutics AG (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 50.73

Change

-4.13 (-7.53)%

Market Cap

USD 0.79B

Volume

2.18M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 7.12 % 0.00 %

+2.80 (+0.33%)

USD 3.68M
ARKG:LSE ARK Genomic Revolution UC.. 7.12 % 0.00 %

+0.02 (+0.33%)

USD 3.68M
ARKG 7.05 % 0.75 %

N/A

N/A
ARCK:LSE ARK Innovation UCITS ETF .. 4.56 % 0.00 %

+2.43 (+0.33%)

USD 0.01B
ARKK:LSE ARK Innovation UCITS ETF .. 4.56 % 0.00 %

+0.02 (+0.33%)

USD 0.01B
ARKK ARK Innovation ETF 4.49 % 0.75 %

-0.97 (0.33%)

USD 6.51B
NXTE Investment Managers Serie.. 4.01 % 0.00 %

-0.20 (0.33%)

N/A
LS:CA 3.11 % 2.21 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.96% 50% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.96% 50% F 31% F
Trailing 12 Months  
Capital Gain -8.26% 47% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.26% 47% F 32% F
Trailing 5 Years  
Capital Gain -7.86% 68% D+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.86% 68% D+ 37% F
Average Annual (5 Year Horizon)  
Capital Gain 13.03% 60% D- 66% D+
Dividend Return 13.03% 60% D- 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 69.14% 51% F 29% F
Risk Adjusted Return 18.85% 76% C+ 53% F
Market Capitalization 0.79B 94% A 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.53 37% 62%
Price/Book Ratio 1.99 57% 48%
Price / Cash Flow Ratio -15.68 84% 86%
Price/Free Cash Flow Ratio 14.16 5% 26%
Management Effectiveness  
Return on Equity -14.00% 91% 48%
Return on Invested Capital -12.00% 81% 37%
Return on Assets -9.77% 89% 35%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.